Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | pp65 Dendritic Cell Vaccine + Sargramostim |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Sargramostim | Leukine | GM-CSF|Prokine | ||
| pp65 Dendritic Cell Vaccine | pp65 DC Vaccine | Pp65 dendritic cell vaccine is a cancer vaccine composed of autologous dendritic cells modified to express pp65, which potentially results in increased immune response against pp65-expressing tumors (PMID: 25762141, PMID: 28411277). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02465268 | Phase II | pp65 Dendritic Cell Vaccine + Sargramostim | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (ATTAC-II) | Completed | USA | 0 |